株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:シェーグレン症候群

Market Spotlight: Sjogren's Syndrome

発行 Datamonitor Healthcare 商品コード 594582
出版日 ページ情報 英文 34 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
注目市場の分析:シェーグレン症候群 Market Spotlight: Sjogren's Syndrome
出版日: 2019年08月29日 ページ情報: 英文 34 Pages
概要

当レポートでは、シェーグレン症候群 (乾燥症候群) の治療薬市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法および治験・認可状況、シェーグレン症候群治療薬市場の動向見通し (今後10年間分)、資本取引の動き、現在開発中の治験の進行状況などを調査しております。

分析のポイント

疾患の背景事情

治療方法

  • ドライアイ
  • ドライマウス
  • その他の腺関連の疾患発現
  • 腺以外の疾患発現

疫学

上市済み医薬品

  • 各国での認証状況

パイプライン上の医薬品

今後の市場の主な動き

ライセンス契約・資産買収取引 (1件)

母体特許

治験情勢

  • スポンサー数:ステータス別
  • スポンサー数:フェーズ (相) 別

関連分析

  • 処方薬の情報

付録

目次
Product Code: DMKC0182069

This Market Spotlight report covers the Sjogren's syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways:

Datamonitor Healthcare estimates that in 2018, there were approximately 2.3 million prevalent cases of primary Sjogren's syndrome worldwide, and forecasts that number to increase to 2.5 million prevalent cases by

2027. Primary Sjogren's syndrome has a female predominance. Globally, Datamonitor Healthcare estimates that in 2018, 90.4% of cases aged 15 years and over were female.

Evoxac, a muscarinic agonist specific to M1 receptors, and LO2A, which contains isotonic glycerol and 0.015% sodium hyaluronate, are the only approved drugs for Sjogren's syndrome.

The majority of industry-sponsored drugs in active clinical development for Sjogren's syndrome are in Phase II, with only one drug in Phase III.

Therapies in mid-to-late-stage development for Sjogren's syndrome focus on a wide variety of targets. The pipeline drugs for Sjogren's syndrome are administered via the oral, intravenous, and subcutaneous routes.

High-impact upcoming events for drugs in the Sjogren's syndrome space comprise topline Phase II trial results for GS-9876, filgotinib, and Benlysta SC.

The overall likelihood of approval of a Phase I arthritis asset is 10.5%, and the average probability a drug advances from Phase III is 79.7%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 8.8 years in the overall autoimmune/immunology space.

There have been only four licensing and asset acquisition deals involving Sjogren's syndrome drugs during 2014-19. The exclusive licensing and collaboration agreement between Eli Lilly and Hanmi for $690m, regarding the development and commercialization of Hanmi's oral BTK inhibitor HM71224 for the treatment of autoimmune and other diseases, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Sjogren's syndrome have been in the early and mid-phases of development, with 71% of trials in Phase I-II, and only 29% in Phase III-IV.

The US has a substantial lead in the number of Sjogren's syndrome clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the Sjogren's syndrome space is dominated by completed trials. Roche has the highest number of completed clinical trials for Sjogren's syndrome, with eight trials.

Novartis leads the industry sponsors with the highest overall number of clinical trials for Sjogren's syndrome, followed by BristolMyers Squibb.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Dry eyes
  • Dry mouth
  • Other glandular manifestations
  • Extraglandular manifestations

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • RSLV-132 for Sjogren's Syndrome (June 13, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Advanz Obtains Two Commercial Products From Eisai

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of primary Sjogren's syndrome, 2018-27
  • Figure 2: Overview of pipeline drugs for Sjogren's syndrome in the US
  • Figure 3: Pipeline drugs for Sjogren's syndrome, by company
  • Figure 4: Pipeline drugs for Sjogren's syndrome, by drug type
  • Figure 5: Pipeline drugs for Sjogren's syndrome, by classification
  • Figure 6: RSLV-132 for Sjogren's Syndrome (June 13, 2019): Phase II - Study 132-04
  • Figure 7: Key upcoming events in Sjogren's syndrome
  • Figure 8: Probability of success in the Sjogren's syndrome pipeline
  • Figure 9: Licensing and asset acquisition deals in Sjogren's syndrome, 2014-19
  • Figure 10: Parent patents in Sjogren's syndrome
  • Figure 11: Clinical trials in Sjogren's syndrome
  • Figure 12: Top 10 drugs for clinical trials in Sjogren's syndrome
  • Figure 13: Top 10 companies for clinical trials in Sjogren's syndrome
  • Figure 14: Trial locations in Sjogren's syndrome
  • Figure 15: Sjogren's syndrome trials status
  • Figure 16: Sjogren's syndrome trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of primary Sjogren's syndrome, 2018-27
  • Table 2: Prevalent cases of primary Sjogren's syndrome, by gender, 2018
  • Table 3: Prevalence of primary Sjogren's syndrome, by gender, 2018
  • Table 4: Marketed drugs for Sjogren's syndrome
  • Table 5: Pipeline drugs for Sjogren's syndrome in the US
  • Table 6: RSLV-132 for Sjogren's Syndrome (June 13, 2019)
Back to Top